1887

Abstract

The aim of the study was to select, from a panel of candidate European human immunodeficiency virus type 1 (HIV-1) clade B primary virus isolates, one isolate based on replication properties in chimpanzee peripheral blood mononuclear cells (PBMC). Secondly, to evaluate the kinetics of primary infection of the selected isolate at two different doses in two mature, outbred chimpanzees (). Four different low passage, human PBMC-cultured ‘primary’ HIV-1 isolates with European clade B consensus sequence were compared for their ability to replicate in chimpanzee versus human PBMC. The isolate which yielded the highest titre and most vigorous cytopathic effect in chimpanzee PBMC was evaluated for coreceptor usage and chosen for evaluation . Only the HIV-1 isolate replicated in chimpanzee PBMC at detectable levels. This isolate was demonstrated to utilize CCR4, CCR5 and CXCR4 co-receptors and could be inhibited by -chemokines. Infection of chimpanzees was demonstrated by viral RNAand DNAPCR analysis, both in plasma as well as in PBMC and lymph node cells as early as 3 weeks after inoculation. Antibodies developed within 6 weeks and continued to increase to a maximum titre of approximately 12800, thereafter remaining in this range over the follow-up period of 2 years. Compared to cell line-adapted HIV-1 isolates there were slight but no dramatic differences in the kinetics of infection of chimpanzees with this particular primary isolate.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-12-2895
1998-12-01
2022-05-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/12/9880002.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-12-2895&mimeType=html&fmt=ahah

References

  1. Arthur L. O., Bess J.Jr Waters D. J., Pyle S. W., Kelliher J. C., Nara P. L., Krohn K., Robey W. G., Langlois A. J., Gallo R. C. 1989; Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. Journal of Virology 63:5046–5053
    [Google Scholar]
  2. Berman P. W., Groopman J. E., Gregory T., Clapham P. R., Weiss R. A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L. A. 1988; Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proceedings of the National Academy of Sciences, USA 85:5200–5204
    [Google Scholar]
  3. Bogers W. M., Dubbes R., ten Haaft P., Niphuis H., Cheng-Mayer C., Stahl-Hennig C., Hunsmann G., Kuwata T., Hayami M., Jones S., Ranjbar S., Almond N., Stott J., Rosenwirth B., Heeney J. L. 1997a; Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology 236:110–117
    [Google Scholar]
  4. Bogers W. M., Koornstra W. H., Dubbes R. H., Nara P., Buijs L., Heeney J. L. 1997b; Potent HIV-1 inhibiting soluble factor from chimpanzee peripheral blood cells. In Research in HIV and Cytokines pp. 211–215 Guenounou M. Edited by Paris: Inserm;
    [Google Scholar]
  5. Bruck C., Thiriart C., Fabry L., Francotte M., Pala P., Van Opstal O., Culp J., Rosenberg M., De Wilde M., Heidt P., Heeney J. L. 1994; HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12:1141–1148
    [Google Scholar]
  6. Girard M., Kieny M. P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E., Fultz P. 1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88:542–546
    [Google Scholar]
  7. Girard M., Meignier B., Barre-Sinoussi F., Kieny M. P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K., Fultz P. 1995; Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. Journal of Virology 69:6239–6248
    [Google Scholar]
  8. Groenink M., Fouchier R. A., de Goede R. E., de Wolf F., Gruters R. A., Cuypers H. T., Huisman H. G., Tersmette M. 1991; Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. Journal of Virology 65:1968–1975
    [Google Scholar]
  9. Heeney J., Bogers W., Buijs L., Dubbes R., ten Haaft P., Koornstra W., Niphuis H., Nara P., Teeuwsen V. 1996; Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS. Immunology Letters 51:45–52
    [Google Scholar]
  10. Heeney J. L., van Els C., de Vries P., ten Haaft P., Otting N., Koornstra W., Boes J., Dubbes R., Niphuis H., Dings M., Cranage M., Norley S., Jonker M., Bontrop R. E., Osterhaus A. 1994; Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. Journal of Experimental Medicine 180:769–774
    [Google Scholar]
  11. Kärber G. 1931; Beitrag zue kollektiven Behandlung pharmakologischer Reinhenversuche. Archiv für Experimentelle Pathologie und Pharmakologie 162:480–487
    [Google Scholar]
  12. Kozak S. L., Platt E. J., Madani N., Ferro F.Jr Peden K., Kabat D. 1997; CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immuno-deficiency virus type 1. Journal of Virology 71:873–882
    [Google Scholar]
  13. Murthy K. K., Cobb E. K., el Amad Z., Ortega H., Hsueh F. C., Satterfield W., Lee D. R., Kalish M. L., Haigwood N. L., Kennedy R. C., Steimer K. S., Schultz A., Levy J. A. 1996; Titration of a vaccine stock preparation of human immunodeficiency virus type 1 SF2 in cultured lymphocytes and in chimpanzees. AIDS Research and Human Retroviruses 12:1341–1348
    [Google Scholar]
  14. Myers G., Korber B., Wain-Hobson S., Jeang K.-T., Henderson L. E., Pavlakis G. N. 1994 Human retroviruses and AIDS database Los Alamos, NM: Los Alamos National Laboratory;
    [Google Scholar]
  15. Sauermann U., Schneider J., Mous J., Brunckhorst U., Schedel I., Jentsch K. D., Hunsmann G. 1990; Molecular cloning and characterization of a German HIV-1 isolate. AIDS Research and Human Retroviruses 6:813–823
    [Google Scholar]
  16. Schuitemaker H., Kootstra N. A., Groenink M., De Goede R. E., Miedema F., Tersmette M. 1992; Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Research and Human Retroviruses 8:1679–1682
    [Google Scholar]
  17. Shibata R., Hoggan M. D., Broscius C., Englund G., Theodore T. S., Buckler-White A., Arthur L. O., Israel Z., Schultz A., Lane H. C. 1995; Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. Journal of Virology 69:4453–4462
    [Google Scholar]
  18. Simmons G., Wilkinson D., Reeves J. D., Dittmar M. T., Beddows S., Weber J., Carnegie G., Desselberger U., Gray P. W., Weiss R. A., Clapham P. R. 1996; Primary, syncytium-inducing human immuno-deficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. Journal of Virology 70:8355–8360
    [Google Scholar]
  19. ten Haaft P. J. F., Cornelissen M., Goudsmit J., Koornstra W., Dubbes R., Niphuis H., Peeters M., Thiriart C., Bruck C., Heeney J. L. 1995; Virus load in chimpanzees infected with human immunodeficiency virus type 1 : effect of pre-exposure vaccination. Journal of General Virology 76:1015–1020
    [Google Scholar]
  20. Zhang L., Huang Y., He T., Cao Y., Ho D. D. 1996; HIV-1 subtype and second-receptor use. Nature 383:768
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-12-2895
Loading
/content/journal/jgv/10.1099/0022-1317-79-12-2895
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error